Quick Answer
DNA X, Inc. reported Total Revenue of $58.30 million for fiscal year 2024.
DNA X, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $58.30M -37.7% |
$93.63M +34.1% |
$69.83M +28.0% |
$54.57M -14.7% |
$63.99M -45.0% |
$116.25M -14.3% |
| Revenue (ASC 606) | $50.92M -45.6% |
$93.63M +34.1% |
$69.83M +28.0% |
$54.57M -14.7% |
$63.99M -45.0% |
$116.25M -14.3% |
| Net Income | -$33.65M -37286.7% |
-$90.0K +99.4% |
-$14.09M +63.5% |
-$38.63M -29.0% |
-$29.93M -15.9% |
-$25.83M -2123.0% |
| Diluted EPS | -$7.13 -35550.0% |
-$0.02 +95.9% |
-$0.49 | — | — | — |
| Total Assets | $39.74M -29.1% |
$56.04M +4.4% |
$53.69M +30.7% |
$41.09M -18.3% |
$50.31M -9.3% |
$55.46M -17.6% |
| Cash and Equivalents | $5.34M -43.1% |
$9.40M -28.9% |
$13.21M +17.6% |
$11.23M -49.3% |
$22.14M +96.0% |
$11.30M -13.4% |
| Long-Term Debt | — | — | — | $66.0K -64.3% |
$185.0K -48.9% |
$362.0K -97.3% |
| Stockholders Equity | -$5.70M -125.5% |
$22.37M +11.6% |
$20.05M +7.6% |
$18.63M -34.4% |
$28.41M +11.3% |
$25.52M +397.7% |
| R&D Expense | $14.23M +703.3% |
$1.77M -77.8% |
$7.97M -54.9% |
$17.70M +9.1% |
$16.22M -37.8% |
$26.06M +12.1% |
| Operating Income | -$33.64M -6657.3% |
$513.0K +103.6% |
-$14.29M +62.4% |
-$38.00M -29.9% |
-$29.26M -30.7% |
-$22.38M -514.9% |
| Gross Profit | $9.92M -48.7% |
$19.32M +66.3% |
$11.62M +81.2% |
$6.41M -57.8% |
$15.21M -55.9% |
$34.51M -28.2% |
| Shares Outstanding | 4.98M +12.6% |
4.43M -89.1% |
40.77M +116.8% |
18.81M +183.6% |
6.63M -67.6% |
20.44M +31.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $16.21M | +7.9% | +44.9% |
| Revenue (ASC 606) | September 30, 2025 | $16.21M | +7.9% | +44.9% |
| Net Income | September 30, 2025 | -$4.75M | -89.2% | +36.4% |
| Diluted EPS | September 30, 2025 | -$4.83 | +48.2% | -511.4% |
| Total Assets | September 30, 2025 | $40.22M | -18.2% | +11.5% |
| Cash and Equivalents | September 30, 2025 | $2.14M | -76.4% | +6.5% |
| Long-Term Debt | September 30, 2022 | $37.0K | -50.0% | +23.3% |
| Stockholders Equity | September 30, 2025 | -$701.0K | -104.6% | +47.5% |
| R&D Expense | September 30, 2025 | $181.0K | -74.7% | -80.1% |
| Operating Income | September 30, 2025 | -$3.98M | -67.5% | +40.9% |
| Gross Profit | September 30, 2025 | $1.82M | -57.1% | +114.9% |
| Shares Outstanding | September 30, 2025 | 1.02M | -79.2% | -90.2% |
- DNA X, Inc. reported Total Revenue of $58.30 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -37.7% in Total Revenue compared to the prior fiscal year.
- DNA X, Inc. reported Revenue (ASC 606) of $50.92 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -45.6% in Revenue (ASC 606) compared to the prior fiscal year.
- DNA X, Inc. reported Net Income of -$33.65 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -37286.7% in Net Income compared to the prior fiscal year.
- DNA X, Inc. reported Diluted EPS of $7.13 per share (loss) for fiscal year 2024.
- DNA X, Inc. showed a decrease of -35550.0% in Diluted EPS compared to the prior fiscal year.
- DNA X, Inc. reported Total Assets of $39.74 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -29.1% in Total Assets compared to the prior fiscal year.
- DNA X, Inc. reported Cash and Equivalents of $5.34 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -43.1% in Cash and Equivalents compared to the prior fiscal year.
- DNA X, Inc. reported Long-Term Debt of $66.0 thousand for fiscal year 2021.
- DNA X, Inc. showed a decrease of -64.3% in Long-Term Debt compared to the prior fiscal year.
- DNA X, Inc. reported Stockholders Equity of -$5.70 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -125.5% in Stockholders Equity compared to the prior fiscal year.
- DNA X, Inc. reported R&D Expense of $14.23 million for fiscal year 2024.
- DNA X, Inc. showed an increase of +703.3% in R&D Expense compared to the prior fiscal year.
- DNA X, Inc. reported Operating Income of -$33.64 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -6657.3% in Operating Income compared to the prior fiscal year.
- DNA X, Inc. reported Gross Profit of $9.92 million for fiscal year 2024.
- DNA X, Inc. showed a decrease of -48.7% in Gross Profit compared to the prior fiscal year.
- DNA X, Inc. reported Shares Outstanding of 4.98 million shares for fiscal year 2024.
- DNA X, Inc. showed an increase of +12.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: